The GLI genes as the molecular switch in disrupting Hedgehog signaling in colon cancer

Oncotarget

Volumn 2, Issue 8, 2011, Pages 638-645

  Mazumdar, Tapati ^a   DeVecchio, Jennifer ^a   Agyeman, Akwasi ^a   Shi, Ting ^a   Houghton, Janet A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Colon carcinoma; DNA damage; Hedgehog signaling

Indexed keywords

ANTINEOPLASTIC AGENT; GANT 61; GLI1 PROTEIN, HUMAN; GLI2 PROTEIN, HUMAN; GLI3 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; NERVE PROTEIN; NUCLEAR PROTEIN; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; CELL DEATH; CELL STRAIN HT29; CELL SURVIVAL; COLON TUMOR; DNA DAMAGE; DNA REPAIR; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL DEATH; CELL SURVIVAL; COLONIC NEOPLASMS; DNA DAMAGE; DNA REPAIR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HT29 CELLS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PYRIDINES; PYRIMIDINES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84856058700     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.310     Document Type: Article

References (48)

1. Katoh Y, Katoh M: Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med 2009, 9(7):873-886.
2. Yu M, Gipp J, Yoon JW, Iannaccone P, Walterhouse D, Bushman W: Sonic hedgehog-responsive genes in the fetal prostate. J Biol Chem 2009, 284(9):5620-5629.
3. Ruiz i Altaba A, Mas C, Stecca B: The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol 2007, 17(9):438-447.
4. Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P, Ruiz i Altaba A: Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med 2009, 1(6-7):338-351.
5. Yoshikawa K, Shimada M, Miyamoto H, Higashijima J, Miyatani T, Nishioka M, Kurita N, Iwata T, Uehara H: Sonic hedgehog relates to colorectal carcinogenesis. J Gastroenterol 2009, 44(11):1113-1117.
6. Bian YH, Huang SH, Yang L, Ma XL, Xie JW, Zhang HW: Sonic hedgehog-Gli1 pathway in colorectal adenocarcinomas. World J Gastroenterol 2007, 13(11):1659-1665.
7. Shi T, Mazumdar T, Devecchio J, Duan ZH, Agyeman A, Aziz M, Houghton JA: cDNA microarray gene expression profiling of hedgehog signaling pathway inhibition in human colon cancer cells. PLoS One 2010, 5(10):e13054.
8. Mazumdar T, DeVecchio J, Shi T, Jones J, Agyeman A, Houghton JA: Hedgehog signaling drives cellular survival in human colon carcinoma cells. Cancer Res 2011, 71(3):1092-1102.
9. Tremblay MR, McGovern K, Read MA, Castro AC: New developments in the discovery of small molecule Hedgehog pathway antagonists. Curr Opin Chem Biol 2010, 14(3):428-435.
10. Low JA, de Sauvage FJ: Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol 2010, 28(36):5321-5326.
11. Mas C, Ruiz i Altaba A: Small molecule modulation of HH-GLI signaling: current leads, trials and tribulations. Biochem Pharmacol 2010, 80(5):712-723.
12. De Smaele E, Ferretti E, Gulino A: Vismodegib, a smallmolecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. Curr Opin Investig Drugs 2010, 11(6):707-718.
13. Lorusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC et al: Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res 2011, 17(8):2502-2511.
14. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR et al: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009, 361(12):1164-1172.
15. Dierks C: GDC-0449--targeting the hedgehog signaling pathway. Recent Results Cancer Res 2010, 184:235-238.
16. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B et al: Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009, 361(12):1173-1178.
17. Ji Z, Mei FC, Xie J, Cheng X: Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem 2007, 282(19):14048-14055.
18. Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V, Beermann F, Ruiz IAA: Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci U S A 2007, 104(14):5895-5900.
19. Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T et al: Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009, 326(5952):572-574.
20. Schnidar H, Eberl M, Klingler S, Mangelberger D, Kasper M, Hauser-Kronberger C, Regl G, Kroismayr R, Moriggl R, Sibilia M et al: Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Res 2009, 69(4):1284-1292.
21. Yoon JW, Kita Y, Frank DJ, Majewski RR, Konicek BA, Nobrega MA, Jacob H, Walterhouse D, Iannaccone P: Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. J Biol Chem 2002, 277(7):5548-5555.
22. Allegra CJ: National Institutes of Health State-of-the-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009. J Natl Cancer Inst. 2010, 102(3):161-9.
23. Mercer KE, Pritchard CA: Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003, 1653(1):25-40.
24. Hinoue T, Weisenberger DJ, Pan F, Campan M, Kim M, Young J, Whitehall VL, Leggett BA, Laird PW: Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One 2009, 4(12):e8357.
25. Marampon F, Bossi G, Ciccarelli C, Di Rocco A, Sacchi A, Pestell RG, Zani BM: MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma. Mol Cancer Ther 2009, 8(3):543-551.
26. Bedogni B, Welford SM, Kwan AC, Ranger-Moore J, Saboda K, Powell MB: Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. Mol Cancer Ther 2006, 5(12):3071-3077.
27. Thiyagarajan S, Bhatia N, Reagan-Shaw S, Cozma D, Thomas-Tikhonenko A, Ahmad N, Spiegelman VS: Role of GLI2 transcription factor in growth and tumorigenicity of prostate cells. Cancer Res 2007, 67(22):10642-10646.
28. Ikram MS, Neill GW, Regl G, Eichberger T, Frischauf AM, Aberger F, Quinn A, Philpott M: GLI2 is expressed in normal human epidermis and BCC and induces GLI1 expression by binding to its promoter. J Invest Dermatol 2004, 122(6):1503-1509.
29. Bai CB, Auerbach W, Lee JS, Stephen D, Joyner AL: Gli2, but not Gli1, is required for initial Shh signaling and ectopic activation of the Shh pathway. Development 2002, 129(20):4753-4761.
30. Curtin JC, Lorenzi MV: Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 2010, 1(7):563-577.
31. Lauth M, Bergstrom A, Shimokawa T, Toftgard R: Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A 2007, 104(20):8455-8460.
32. Mazumdar T, Devecchio J, Agyeman A, Shi T, Houghton JA: Blocking Hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells. Cancer Res 2011, [Epub ahead of print].
33. Dormoy V, Danilin S, Lindner V, Thomas L, Rothhut S, Coquard C, Helwig JJ, Jacqmin D, Lang H, Massfelder T: The sonic hedgehog signaling pathway is reactivated in human renal cell carcinoma and plays orchestral role in tumor growth. Mol Cancer 2009, 8:123.
34. Ruiz i Altaba A: Gli proteins encode contextdependent positive and negative functions: implications for development and disease. Development 1999, 126(14):3205-3216.
35. Lobrich M, Shibata A, Beucher A, Fisher A, Ensminger M, Goodarzi AA, Barton O, Jeggo PA: gammaH2AX foci analysis for monitoring DNA double-strand break repair: strengths, limitations and optimization. Cell Cycle 2010, 9(4):662-669.
36. Carson DA, Lois A: Cancer progression and p53. Lancet 1995, 346(8981):1009-1011.
37. Holzel M, Burger K, Muhl B, Orban M, Kellner M, Eick D: The tumor suppressor p53 connects ribosome biogenesis to cell cycle control: a double-edged sword. Oncotarget 2010, 1(1):43-47.
38. Petak I, Tillman DM, Houghton JA: p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracilleucovorin in human colon carcinoma cell lines. Clin Cancer Res 2000, 6(11):4432-4441.
39. Nojima H: G1 and S-phase checkpoints, chromosome instability, and cancer. Methods Mol Biol 2004, 280:3-49.
40. Hartwell LH, Weinert TA: Checkpoints: controls that ensure the order of cell cycle events. Science 1989, 246(4930):629-634.
41. Sherr CJ: Principles of tumor suppression. Cell 2004, 116(2):235-246.
42. Falck J, Petrini JH, Williams BR, Lukas J, Bartek J: The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways. Nat Genet 2002, 30(3):290-294.
43. Woo RA, Poon RY: Cyclin-dependent kinases and S phase control in mammalian cells. Cell Cycle 2003, 2(4):316-324.
44. Zhu Y, Alvarez C, Doll R, Kurata H, Schebye XM, Parry D, Lees E: Intra-S-phase checkpoint activation by direct CDK2 inhibition. Mol Cell Biol 2004, 24(14):6268-6277.
45. Grady WM: Genomic instability and colon cancer. Cancer Metastasis Rev 2004, 23(1-2):11-27.
46. Frappart PO, Lee Y, Russell HR, Chalhoub N, Wang YD, Orii KE, Zhao J, Kondo N, Baker SJ, McKinnon PJ: Recurrent genomic alterations characterize medulloblastoma arising from DNA double-strand break repair deficiency. Proc Natl Acad Sci U S A 2009, 106(6):1880-1885.
47. Leonard JM, Ye H, Wetmore C, Karnitz LM: Sonic Hedgehog signaling impairs ionizing radiation-induced checkpoint activation and induces genomic instability. J Cell Biol 2008, 183(3):385-391.
48. Snijders AM, Huey B, Connelly ST, Roy R, Jordan RC, Schmidt BL, Albertson DG: Stromal control of oncogenic traits expressed in response to the overexpression of GLI2, a pleiotropic oncogene. Oncogene 2009, 28(5):625-637.